Irreversible egfr inhibitor ekb-569 targets low-let γ-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Aravindan, Natarajan ^b   Thomas Jr , Charles R ^c   Aravindan, Sheeja ^b   Mohan, Aswathi S ^a   Veeraraghavan, Jamunarani ^b   Natarajan, Mohan ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEURONAL APOPTOSIS INHIBITORY PROTEIN; PELITINIB; PROTEIN BIRC2; PROTEIN BIRC5; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; WAY 172569; AMINOQUINOLINE DERIVATIVE; ANILINE DERIVATIVE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RADIOSENSITIZING AGENT; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL FATE; CELL KILLING; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; METABOLISM; PROTEIN DNA BINDING; RNA TRANSLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TONGUE SQUAMOUS CELL CARCINOMA; TRANSACTIVATION; DRUG ANTAGONISM; DRUG EFFECT; GAMMA RADIATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LINEAR ENERGY TRANSFER; PATHOLOGY; RADIATION EXPOSURE; TUMOR CELL LINE; UPREGULATION;

AMINOQUINOLINES; ANILINE COMPOUNDS; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CELL LINE, TUMOR; DNA, NEOPLASM; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; LINEAR ENERGY TRANSFER; NEOPLASM PROTEINS; NF-KAPPA B; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-REL; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84855293765     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029705     Document Type: Article

References (53)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Hunter KD, Parkinson EK, Harrison PR, (2005) Profiling early head and neck cancer. Nat Rev Cancer 5: 127-135.
3. Salomon DS, Brandt R, Ciardiello F, Normanno N, (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232.
4. Woodburn JR, (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250.
5. Arteaga CL, (2001) The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19: 32S-40S.
6. Baeuerle PA, Baltimore D, (1991) Hormonal Control Regulation of Gene Transcription. pp. 409-432 In Molecular Aspects of Cellular Regulation, Cohen, P and Foulkes, JG (eds), Elsevier/North Holland Biomedical Press Amsterdam.
7. Lenardo MJ, Baltimore D, (1989) NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 58: 227-229.
8. Neri A, Chang CC, Lombardi L, Salina M, Corradini P, et al. (1991) B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell 67: 1075-1087.
9. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, et al. (1993) Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci U S A 90: 9901-9905.
10. Tozawa K, Sakurada S, Kohri K, Okamoto T, (1995) Effects of anti-nuclear factor kappa B reagents in blocking adhesion of human cancer cells to vascular endothelial cells. Cancer Res 55: 4162-4167.
11. Orlowski RZ, Baldwin AS Jr, (2002) NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8: 385-389.
12. Yan M, Xu Q, Zhang P, Zhou XJ, Zhang ZY, et al. (2010) Correlation of NF-kappaB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma. BMC Cancer 10: 437.
13. Chen X, Shen B, Xia L, Khaletzkiy A, Chu D, et al. (2002) Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res 62: 1213-1221.
14. Herscher LL, Cook JA, Pacelli R, Pass HI, Russo A, et al. (1999) Principles of chemoradiation: theoretical and practical considerations. Oncology (Williston Park) 13: 11-22.
15. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, et al. (2001) Inhibition of JNK activation through NF-kappaB target genes. Nature 414: 313-317.
16. Sun Y, St Clair DK, Fang F, Warren GW, Rangnekar VM, et al. (2007) The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther 6: 2477-2486.
17. He L, Kim BY, Kim KA, Kwon O, Kim SO, et al. (2007) NF-kappaB inhibition enhances caspase-3 degradation of Akt1 and apoptosis in response to camptothecin. Cell Signal 19: 1713-1721.
18. Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, et al. (2006) Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 6: 107.
19. Magne N, Toillon RA, Bottero V, Didelot C, Houtte PV, et al. (2006) NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett 231: 158-168.
20. Kim BY, Kim KA, Kwon O, Kim SO, Kim MS, et al. (2005) NF-kappaB inhibition radiosensitizes Ki-Ras-transformed cells to ionizing radiation. Carcinogenesis 26: 1395-1403.
21. Forastiere A, Koch W, Trotti A, Sidransky D, (2001) Head and neck cancer. N Engl J Med 345: 1890-1900.
22. Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, Gutkind JS, (2006) Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 8: 733-746.
23. Vlantis AC, Lo CS, Chen GG, Ci Liang N, Lui VW, et al. (2010) Induction of laryngeal cancer cell death by Ent-11-hydroxy-15-oxo-kaur-16-en-19-oic acid. Head Neck 32: 1506-1518.
24. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, et al. (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102: 7665-7670.
25. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
26. Rubin BP, Duensing A, (2006) Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab Invest 86: 981-986.
27. Sequist LV, (2007) Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 12: 325-330.
28. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, et al. (2003) Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem 46: 49-63.
29. Veeraraghavan J, Natarajan M, Aravindan S, Herman TS, Aravindan N, (2011) Radiation-triggered tumor necrosis factor (TNF) alpha-NFkappaB cross-signaling favors survival advantage in human neuroblastoma cells. J Biol Chem 286: 21588-21600.
30. Aravindan N, Shanmugasundaram K, Natarajan M, (2009) Hyperthermia induced NFkappaB mediated apoptosis in normal human monocytes. Mol Cell Biochem 327: 29-37.
31. Baselga J, (2006) Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question. J Clin Oncol 24: 2225-2226.
32. Alroy I, Yarden Y, (1997) The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410: 83-86.
33. Lewis TS, Shapiro PS, Ahn NG, (1998) Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49-139.
34. Chan TO, Rittenhouse SE, Tsichlis PN, (1999) AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 68: 965-1014.
35. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
36. Igney FH, Krammer PH, (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288.
37. Aravindan N, Madhusoodhanan R, Ahmad S, Johnson D, Herman TS, (2008) Curcumin inhibits NFkappaB mediated radioprotection and modulate apoptosis related genes in human neuroblastoma cells. Cancer Biol Ther 7: 569-576.
38. Aravindan N, Madhusoodhanan R, Natarajan M, Herman TS, (2008) Alteration of apoptotic signaling molecules as a function of time after radiation in human neuroblastoma cells. Mol Cell Biochem 310: 167-179.
39. Madhusoodhanan R, Natarajan M, Singh JV, Jamgade A, Awasthi V, et al. (2010) Effect of black raspberry extract in inhibiting NFkappa B dependent radioprotection in human breast cancer cells. Nutr Cancer 62: 93-104.
40. Madhusoodhanan R, Natarajan M, Veeraraghavan J, Herman TS, Aravindan N, (2009) NFkappaB activity and transcriptional responses in human breast adenocarcinoma cells after single and fractionated irradiation. Cancer Biol Ther 8: 765-773.
41. Madhusoodhanan R, Natarajan M, Veeraraghavan J, Herman TS, Jamgade A, et al. (2009) NFkappaB signaling related molecular alterations in human neuroblastoma cells after fractionated irradiation. J Radiat Res (Tokyo) 50: 311-324.
42. Veeraraghavan J, Aravindan S, Natarajan M, Awasthi V, Herman TS, et al. (2011) Neem leaf extract induces radiosensitization in human neuroblastoma xenograft through modulation of apoptotic pathway. Anticancer Res 31: 161-170.
43. Veeraraghavan J, Natarajan M, Herman TS, Aravindan N, (2010) Curcumin-altered p53-response genes regulate radiosensitivity in p53-mutant Ewing's sarcoma cells. Anticancer Res 30: 4007-4015.
44. Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, et al. (2003) Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg 7: 37-43; discussion 43.
45. Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, et al. (2001) Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20: 859-868.
46. Piva R, Belardo G, Santoro MG, (2006) NF-kappaB: a stress-regulated switch for cell survival. Antioxid Redox Signal 8: 478-486.
47. Salvesen GS, Duckett CS, (2002) IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3: 401-410.
48. Cao C, Mu Y, Hallahan DE, Lu B, (2004) XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23: 7047-7052.
49. Lu B, Mu Y, Cao C, Zeng F, Schneider S, et al. (2004) Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 64: 2840-2845.
50. Giagkousiklidis S, Vogler M, Westhoff MA, Kasperczyk H, Debatin KM, et al. (2005) Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res 65: 10502-10513.
51. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, et al. (2003) Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55: 1341-1347.
52. Nakanishi C, Toi M, (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309.
53. Ravi R, Bedi A, (2004) NF-kappaB in cancer-a friend turned foe. Drug Resist Updat 7: 53-67.